CTNM - Company ID 0001855175
Contineum Therapeutics, Inc. trades as CTNM. This page tracks Contineum Therapeutics, Inc. through 153 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Next research step
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-05 |
| Major company event | 8-K | 2026-05-05 |
| Insider sale notice | 144 | 2026-05-01 |
| Insider trade | 4 | 2026-05-01 |
| Annual report to shareholders | ARS | 2026-04-30 |
| Proxy materials | DEFA14A | 2026-04-30 |
The largest companies sharing Contineum Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Contineum Therapeutics, Inc. reported a net loss of $59.98M.